Can vasculitis be present if the complete blood count, differential, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) are all normal?

Yes, Vasculitis Can Absolutely Be Present With Completely Normal CBC, Differential, CRP, and ESR

Vasculitis should never be ruled out based solely on normal inflammatory markers—clinical presentation must drive the diagnosis, and tissue biopsy remains the gold standard when suspicion is high.

Key Evidence Supporting Normal Inflammatory Markers in Vasculitis

Primary CNS Vasculitis

Primary central nervous system vasculitis characteristically presents with normal or only minimally elevated ESR, and other acute-phase reactants are typically normal 1. This is a well-recognized pattern where small-vessel strokes may occur over weeks to months despite persistently normal inflammatory markers. The diagnosis relies on imaging (MRI abnormal in >90% of cases) and ultimately cortical-leptomeningeal biopsy 1.

Giant Cell Arteritis (GCA)

While most GCA patients have elevated inflammatory markers, 4% of biopsy-proven GCA cases present with both normal ESR and CRP 2. More recent case reports confirm this diagnostic conundrum 3, 4. These patients with normal markers tend to have:

• More polymyalgia rheumatica symptoms
• Fewer constitutional symptoms
• Less anemia and thrombocytosis
• Excellent long-term prognosis once diagnosed 5

Critical point: The sensitivity of ESR alone is only 76-86%, while CRP is 97.5%. However, even using both tests together, 1% of GCA cases will have normal values 2, 6. A normal CRP with elevated ESR occurs in 1.7% of cases, and vice versa 6.

ANCA-Associated Vasculitis

For ANCA-associated vasculitides, a negative ANCA does not rule out disease 7. In EGPA (eosinophilic granulomatosis with polyangiitis), only 26-48% are p-ANCA positive (increasing to 75% with renal involvement), meaning the majority may be ANCA-negative 7. The guidelines explicitly state that patients without confirmatory biopsy can be included if clinical picture is compatible with specific investigations suggestive of vasculitis 8.

Diagnostic Algorithm When Vasculitis Is Suspected Despite Normal Labs

1. Prioritize Clinical Features

Look for these specific patterns:

• CNS vasculitis: Headaches, altered consciousness, multifocal neurological events, stroke in young patients 1
• GCA: Temporal tenderness, jaw claudication, vision changes, new headache in patients >50 years 9
• Systemic vasculitis: Fever, multifocal neurological events, unexplained skin lesions, glomerulopathy 1

2. Obtain Tissue Diagnosis

When clinical suspicion is high despite normal inflammatory markers:

• Temporal artery biopsy for suspected GCA—should not be delayed by pending labs 10, 11
• Skin biopsy for cutaneous vasculitis—look for leucocytoclasia, endothelial damage, perivascular fibrin 12
• Brain/meningeal biopsy for primary CNS vasculitis (most specific test) 1

3. Advanced Imaging

• MRI/MRA for CNS vasculitis (abnormal in >90%) 1
• PET/CT for large vessel vasculitis 13
• Vascular ultrasound for temporal arteries and large vessels 10, 13

4. Additional Laboratory Testing

Even with normal ESR/CRP, obtain:

• ANCA testing (but remember negative doesn't exclude disease) 7, 8
• Urinalysis with microscopy for dysmorphic RBCs/casts 8
• Complement levels (C3, C4) for urticarial vasculitis 12
• Serum amyloid A (SAA) may be elevated when ESR/CRP are normal 14

Common Pitfalls to Avoid

1. Never delay treatment for suspected GCA while awaiting biopsy results—vision loss is irreversible 9, 11

2. Don't rely on inflammatory markers alone for monitoring disease activity—they must be interpreted in clinical context 8, 15

3. Recognize that increases in inflammatory markers without clinical symptoms do not warrant treatment escalation—observe and monitor more frequently 11

4. Be aware that IL-6 receptor blockers (tocilizumab) can normalize CRP/ESR even with active disease 15

Treatment Implications

If clinical suspicion for vasculitis is high, initiate treatment even with normal inflammatory markers 9, 1, 11. For GCA specifically, prompt corticosteroid therapy is critical to prevent vision loss in the fellow eye 9. The 2021 ACR/Vasculitis Foundation guidelines emphasize that clinical monitoring should continue long-term regardless of inflammatory marker levels 11.

The evidence is clear: biomarkers like CRP and ESR should be determined regularly as serologic markers of disease activity, but results must be interpreted in the context of clinical findings 8. Normal inflammatory markers provide false reassurance in a small but clinically significant proportion of vasculitis cases.